Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis by Nathaniel Lizak et al.
November 2016 | Volume 7 | Article 2061
Original research
published: 21 November 2016
doi: 10.3389/fneur.2016.00206
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Kenneth Shindler, 
University of Pennsylvania, USA
Reviewed by: 
Larry Allen Abel, 
University of Melbourne, Australia 
Robert Mallery, 
Brigham and Women’s Hospital, USA
*Correspondence:
Owen B. White 
obw@unimelb.edu.au
†Owen B. White and Joanne 
Fielding contributed equally to 
the manuscript.
Specialty section: 
This article was submitted to 
Neuro-Ophthalmology, 






Lizak N, Clough M, Millist L, 
Kalincik T, White OB and Fielding J 
(2016) Impairment of Smooth Pursuit 
as a Marker of Early Multiple 
Sclerosis. 
Front. Neurol. 7:206. 
doi: 10.3389/fneur.2016.00206
impairment of smooth Pursuit as a 
Marker of early Multiple sclerosis
Nathaniel Lizak1,2,3, Meaghan Clough1,3, Lynette Millist4, Tomas Kalincik1,4,  
Owen B. White1,3,4*† and Joanne Fielding1,3,4†
1 Department of Medicine, University of Melbourne, Melbourne, VIC, Australia, 2 Monash School of Medicine, Monash 
University, Melbourne, VIC, Australia, 3 School of Psychological Sciences, Monash Institute of Cognitive and Clinical 
Neurosciences, Monash University, Melbourne, VIC, Australia, 4 Department of Neurology, Royal Melbourne Hospital, 
Melbourne, VIC, Australia
Background: Multiple sclerosis (MS) is a diffuse disease that disrupts wide-ranging 
cerebral networks. The control of saccades and smooth pursuit are similarly dependent 
upon widespread networks, with the assessment of pursuit offering an opportunity to 
examine feedback regulation. We sought to characterize pursuit deficits in MS and to 
examine their relationship with disease duration.
Methods: Twenty healthy controls, 20 patients with a clinically isolated syndrome 
(CIS), and 40 patients with clinically definite MS (CDMS) participated. Thirty-six trials of 
Rashbass’ step–ramp paradigm of smooth pursuit, evenly split by velocity (8.65°, 17.1°, 
and 25.9°/s) and ramp direction (left/right), were performed. Four parameters were 
measured: latency of pursuit onset, closed-loop pursuit gain, number of saccades, and 
summed saccade amplitudes during pursuit. For CDMS patients, these were correlated 
with disease duration and Expanded Disability Status Scale (EDSS) score.
results: Closed-loop pursuit gain was significantly lower in CIS than controls at all 
speeds. CDMS gain was lower than controls at medium pursuit velocity. CDMS patients 
also displayed longer pursuit latency than controls at all velocities. All patients accumu-
lated increased summed saccade amplitudes at slow and medium pursuit speeds, and 
infrequent high-amplitude saccades at the fast speed. No pursuit variable significantly 
correlated with EDSS or disease duration in CDMS patients.
conclusion: Smooth pursuit is significantly compromised in MS from onset. Low pursuit 
gain and increased saccadic amplitudes may be robust markers of disseminated pathol-
ogy in CIS and in more advanced MS. Pursuit may be useful in measuring early disease.
Keywords: multiple sclerosis, smooth pursuit, clinically isolated syndrome, ocular motor system, neuro-ophthalmology
inTrODUcTiOn
Multiple sclerosis (MS) is characterized by chronic episodic and progressive inflammatory degenera-
tion of the central nervous system, leading to significant degradation of quality of life (1). While 
episodes of neurological damage to “eloquent” regions producing discrete radiological lesions are 
considered the hallmark of MS (2), extensive damage to neurological networks can be observed from 
onset (3–9). However, quantitative MRI techniques used to establish this pathology are expensive 
and time consuming (10), and do not directly mirror functional impairment. Similarly, standard 
clinical assessment tools remain fairly insensitive to subtle network injury, generating a need for 
novel ways of measuring such pathology.
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Previous work done by our group has highlighted the utility 
of ocular motor assessment in quantifying pathological changes 
from the earliest inception of the disease, known as a clinically 
isolated syndrome (CIS), and in more advanced MS (11–17). 
This work has focused on the assessment of saccades, rapid eye 
movements that center a visual target onto the fovea, and impli-
cate a widespread neuronal network (11, 18). However, other 
outputs of the ocular motor system have not been investigated 
as extensively.
Smooth pursuit is another form of eye movement that enables 
tracking of objects moving in space. The smooth pursuit system 
incorporates closed-loop neuronal systems, continuously utiliz-
ing real-time negative feedback, for the critical task of maintaining 
optimal fixation of a target in motion by aligning it with the fovea 
(19). While pursuit has traditionally been viewed as a reflexive 
behavior under feedback control, recent evidence suggests it is 
reliant on neural networks similar to those involved in saccade 
generation, with pursuit and saccades merely different outcomes 
of the same sensorimotor system (20). However, there are funda-
mental differences in their execution: while saccades are a single 
pseudo-ballistic movement, pursuit requires constant regulation 
by feedback loops (19). Assessing smooth pursuit allows not 
only the investigation of movement generation, as with saccades, 
but also affords a novel opportunity to examine the integrity of 
combined visual and motor feedback loops, and the impairment 
of feedback control.
Consequently, pursuit may offer an independent measure 
of widespread network damage in MS and possibly provide a 
differential marker in staging disease. Studies have investigated 
pursuit in MS, with evidence demonstrating poorer pursuit gain 
(21, 22). However, there is currently no understanding about 
when pursuit deficits first manifest, and whether these deficits 
deteriorate with increasing disease activity, providing a marker 
for monitoring disease.
We aimed to characterize pursuit failure in MS, establish when 




Twenty patients with CIS, 40 patients with clinically definite MS 
(CDMS), and 20 neurologically healthy controls participated. 
CIS patients were included based on an initial neurological 
episode, suggestive of MS, with MRI evidence of demyelination. 
CDMS patients were included based on a definitive diagnosis 
of MS as per the McDonald criteria (2). Healthy controls were 
recruited from the community; exclusion criteria for this group 
included a history of traumatic head injury, neurological or 
psychiatric disorder, drug abuse, or regular intake of psychoac-
tive drugs.
All patients were recruited through either Cabrini or Royal 
Melbourne Hospitals, Australia, and tested at the latter. Ethics 
approval was granted by the Melbourne Health Human Research 
Ethics Committee, and all participants gave their written 
informed consent prior to inclusion, in accordance with the 
declaration of Helsinki.
smooth Pursuit Testing
All participants were tested using Rashbass’ step–ramp 
paradigm of smooth pursuit at constant velocity (23). At the 
time of testing, no CIS or CDMS patients were suffering from 
exacerbated symptomatology or demonstrated any evidence of 
active disease, and all participants had adequate visual acuity 
to perform the task. Testing was conducted as part of a larger 
set of ocular motor assessments, the results of which have been 
published elsewhere (12, 13).
Participants were seated in a darkened room, directly in front 
of the display monitor, at a distance of 840 mm. Horizontal ocu-
lar displacement was recorded using the EyeLink II dark pupil, 
video-oculography system (SR-Research Ltd., Mississauga, ON, 
Canada). This is a high-resolution (noise limited at <0.01°), high-
acquisition rate (500 Hz) system, with three miniature cameras 
mounted on a headband. All screen-based stimuli were generated 
using Experiment Builder (version 1.10.165), and displayed on a 
22″ CRT monitor.
Each trial of the step–ramp paradigm commenced with the 
presentation of a fixation target centrally: a 20 × 20 pixel white 
square ring, subtending 0.5° visual angle. The fixation target was 
maintained for a variable period: 1000, 1500, 2000, or 2500 ms, 
equally weighted between ramp speeds and directions. This 
fixation target was then replaced by the task target, a small green 
square 21 × 21 pixels and subtending approximately 0.5° visual 
angle. The green square appeared either right or left of the fixa-
tion target [i.e., the “step” (23)] and then moved in the opposite 
direction at a constant velocity [the “ramp” (23)] through the 
center position and toward the opposite side of the screen. The 
trial terminated when the target reached the 10° position either 
left or right of center. Participants were instructed to follow the 
target as it moved through the screen. Figure 1 illustrates the task.
Each participant performed 36 individual trials of this 
paradigm, broken up into 3 blocks of 12, with a brief rest break 
between each block. Trials were evenly split by ramp direction 
(left/right) and velocity: 8.65°, 17.1°, and 25.9°/s. Greater step 
magnitudes were utilized at greater ramp velocities (1.4°, 2.69°, 
and 4.12°, respectively), calculated to provide a latency of about 
160 ms (24) for the target to reach the center of the screen from 
the initial eccentric position. This was intended to lower the 
likelihood of a saccade being triggered at pursuit initiation. Trials 
were arranged in a randomized order with regard to ramp speed 
and direction, which was identical for all participants.
Data analysis
Latency of pursuit onset, closed-loop pursuit gain, and the 
number and amplitudes of saccades made during each trial were 
examined. Analysis of each of these variables was conducted 
separately at each pursuit speed (8.65°, 17.1°, and 25.9°/s).
Pursuit onset was manually determined as the point at which 
the eye commenced net movement in the direction of the target, 
with no or only minor movement in the opposite direction. 
Latency was calculated as the time from target step to pursuit onset. 
Excluded from the calculation of latency were all trials beginning 
with a saccade, or where pursuit onset was delayed by saccades, 
blinks, and purposeless eye movements (e.g., square wave jerks), 
or where onset could not be identified due to ocular drift.
FigUre 1 | Task illustration. Illustration of a step–ramp pursuit trial. The target is initially central (A). It is then suddenly replaced by a target either left or right of 
center [target step; (B)]. The target then moves at constant velocity to the other side of the screen [target ramp; (C)] until reaching a position of 10° either left or right 
of center (D).
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Closed-loop pursuit gain was calculated as the ratio of target 
to eye velocity during closed-loop pursuit (i.e., smooth tracking 
of the target with online correction). This was evaluated during 
a single continuous period of smooth pursuit within each trial, 
excluding any saccades, blinks, and square wave jerks, where the 
participant displayed their most optimal pursuit (i.e., greatest 
gain). To ensure that this was not an open-loop (i.e., predictive) 
smooth eye movement, this period was always selected at least 
200 ms after pursuit onset. Rarely, if less than 20 ms of pursuit was 
available, usually due to excessive blinking, trials were removed 
from the analysis. Through this calculation, a gain value of 1 was 
effectively “perfect” pursuit, and lower the gain value, the worse 
the participant’s ability to pursue the target.
Finally, saccade counts and amplitudes were obtained during 
each step–ramp trial. All saccades performed from target step 
through to the end of the trial (when the target reached the 10° 
position) were included. Automated saccade detection identified 
periods of the segment where velocity magnitude (i.e., independ-
ent of positive or negative sign) exceeded background velocity by 
more than 5°/s and then declined back to below this level. If the 
peak velocity between these two points was <45°/s (likely baseline 
drift) or >400°/s (likely blink or artifact), the section was auto-
matically discarded. All traces were visually inspected to identify 
additional saccades not detected automatically, and to remove 
any blinking, square wave jerks, or artifact incorrectly labeled as a 
saccade (19). Saccade counts simply reflected the number of sac-
cades made during the trial. Summed saccade amplitudes were 
calculated as the sum of amplitudes of all saccades performed 
during each pursuit trial, as a measure of saccadic interruption 
of pursuit.
Saccades measured were the combination of all catch-up, back-
up, and task-inappropriate saccades performed by participants.
statistical analysis
Statistical analysis was carried out using R version 3.1.0 (http://
www.R-project.org). All hypotheses were tested at the two-
tailed 0.05 level of statistical significance. Planned compari-
sons between individual groups were conducted using Welch’s 
t-tests (or, where distributions were non-normal, Wilcoxon 
rank-sum tests) to determine differences in pursuit latency, 
gain, and saccade counts and summed amplitudes. These vari-
ables were also correlated with disease duration and Expanded 
Disability Status Scale (EDSS) step in the CDMS group, using 
Pearson’s (r) correlations or Spearman’s rho, depending on 
distributions.
resUlTs
Demographic and clinical characteristics of the participants 
are summarized in Table  1. CDMS patients were significantly 
older than the other two groups, which would be expected given 
that, by definition, they have suffered MS for longer than CIS 
patients. However, no relationships were found, for any group, 
between markers of pursuit performance and participant age. 
Consequently, age was not considered as a factor.
Group means and differences for all variables are demonstrated 
in Figures 2–5, and statistical results for all comparisons between 
controls and patient groups are shown in Table 2.
Pursuit latency
Clinically definite MS patients demonstrated significantly greater 
latencies than healthy controls at all pursuit velocities. Although 
CIS patients had longer latencies than controls, but shorter than 
CDMS patients, these trends were not statistically significant. 
Figure 2 illustrates latency values for all groups.
FigUre 4 | comparison of summed saccade amplitudes. Differences in 
summed saccade amplitudes (°/trial) at slow (8.65°/s), medium (17.1°/s), and 
fast (25.9°/s) pursuit speeds. Bars: mean summed saccade amplitude. Error 
bars: SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
FigUre 3 | comparison of pursuit gain. Differences in pursuit gain at 
slow (8.65°/s), medium (17.1°/s), and fast (25.9°/s) pursuit speeds. Bars: 
mean gain. Error bars: SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
FigUre 2 | comparison of pursuit latency. Differences in pursuit latency 
(milliseconds) at slow (8.65°/s), medium (17.1°/s), and fast (25.9°/s) pursuit 
speeds. Bars: mean latency. Error bars: SEM. *P < 0.05, **P < 0.01, 
***P < 0.001.
TaBle 1 | Participant characteristics.
cDMs cis controls
Number 40 20 20
Age, years (mean ± SD) 43.0 ± 11.4 33.3 ± 8.2 35.1 ± 13.1
Gender (number female, % female) 37, 93 16, 80 13, 65
EDSS (mean ± SD) 1.3 ± 1.4 – –
Disease duration, years (mean ± SD) 8.0 ± 5.9 – –
EDSS, Expanded Disability Status Scale; CDMS, clinically definite multiple sclerosis; 
CIS, clinically isolated syndrome.
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Pursuit gain
At all pursuit speeds, CIS patients exhibited significantly lower 
closed-loop pursuit gain than healthy controls. At the medium 
pursuit velocity (17.1°/s), where this difference was most pro-
nounced, CDMS patients also displayed significantly lower gain 
than controls. At slow pursuit velocity, gain slightly above 1 for 
all groups implies that eye velocity consistently exceeded target 
velocity. Figure 3 demonstrates these results.
saccades during Pursuit
At slow and medium pursuit velocities (8.65°/s and 17.1°/s), 
both CIS and CDMS groups demonstrated significantly greater 
summed saccade amplitudes than healthy controls. CDMS 
patients also performed more saccades than controls at the slow-
est velocity. At medium velocity, no differences were observed in 
saccade counts. At the fastest pursuit velocity (25.9°/s), there were 
no significant differences in summed saccade amplitudes; how-
ever, controls displayed a greater saccade count than both CIS and 
CDMS groups. These differences are shown in Figures 4 and 5.
Although saccades were initially categorized as catch-up, back-
up, and task-inappropriate, catch-up saccades predominated. 
Indeed, of all saccades made by trial participants, 78.8–87.4% in 
slow, 95.6–97.0% in medium, and 97.5–98.6% in fast pursuit were 
of the catch-up type. Of the mean summed saccade amplitudes, 
the contribution made by catch-up saccades was: 79.2–87.6% in 
slow, 96.2–98.4% in medium, and 98.7–99.7% in fast pursuit. 
There were no significant differences between groups in numbers 
and amplitudes of back-up and task-inappropriate saccades, and 
comparisons of all saccade types or exclusively of catch-up sac-
cades yielded identical results (latter not shown). Hence, saccade 
types were collapsed, and the analysis, as reported above, was 
carried out on all saccades performed.
There were no significant differences between CIS and 
CDMS groups for any of the pursuit variables (latency, gain, and 
saccades).
correlations with clinical Variables
There was a near-significant positive correlation between 
CDMS latency at the slowest velocity (8.65°/s) and EDSS score 
TaBle 2 | Pursuit comparisons.





















Statistical values for comparisons between patient groups (CIS and CDMS) and 
controls. Where distributions were normal, t-tests were utilized, and the value of t 
and the degrees of freedom (DF) are displayed. Where assumptions were violated, 




CIS, clinically isolated syndrome; CDMS, clinically definite multiple sclerosis.
FigUre 5 | comparison of saccade counts. Differences in saccade 
counts (saccades/trial) at slow (8.65°/s), medium (17.1°/s), and fast (25.9°/s) 
pursuit speeds. Bars: mean saccade count. Error bars: SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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(Spearman’s rho = 0.31, P = 0.055). No other CDMS pursuit vari-
ables (gain, latency, and saccade amplitudes and counts) at any 
velocities correlated with either EDSS or disease duration (data 
not shown).
DiscUssiOn
While saccadic impairments are now a recognized feature of 
MS (11), previous research on smooth pursuit in MS has been 
restricted to descriptions of poor gain and a preponderance of 
catch-up saccades in patients with long-standing CDMS (21, 
22). Our study further characterizes these deficits, and is the 
first to investigate pursuit at the earliest stages of disease. Using 
a step–ramp paradigm, we found that closed-loop pursuit gain is 
lowered in patients with CIS, the first clinically detectable presen-
tation of MS, and remains abnormally low as disease progresses to 
CDMS. Simultaneously, there is a tendency for increased saccade 
generation during pursuit, with abnormally elevated saccade 
amplitudes observed in both CIS and CDMS patients. Pursuit 
latency is delayed in CDMS.
Our results suggest that smooth pursuit is substantially 
impaired at the inception of clinical disease (CIS), similar to 
saccades (12, 13). While saccades and smooth pursuit eye move-
ments are subserved by a largely overlapping neural network (20), 
pursuit involves an additional level of complexity, involving visual 
feedback control of pursuit performance; this likely explains 
the seeming vulnerability of pursuit to minor disruptions to its 
subserving networks, as likely occurs in CIS.
Indeed, poor pursuit gain in all patients is highly suggestive of 
impairments in feedback loops (failure of both afferent feedback 
and the subsequent efferent generation), occurring from disease 
onset. The observed tendency for catch-up saccades likely reflects 
a compensatory mechanism for inadequate pursuit, and that 
when the nexus between feedback regulation and smooth pursuit 
generation breaks, saccades are generated.
Importantly, we analyzed gain during a short, optimal seg-
ment of closed-loop smooth eye movement. This was done with 
the deliberate intent of assessing the maximal capacity of the 
system to generate pursuit; saccade amplitudes were used as a 
marker of overall pursuit maintenance and failure to generate 
pursuit consistently. Given that reduced gain was observed 
during the optimal segment of pursuit in this pilot, overall gain 
should also be examined, which is best evaluated through a 
sinusoidal task.
Partly, analysis of gain during optimal pursuit may explain 
why, at slow target velocity, control gain was above 1, and the CIS 
group displayed a significantly reduced pursuit gain with a mean 
of 1.01 (which is seemingly normal). However, this also suggests 
that an optimal smooth eye movement, at this target velocity, 
is somewhat predictive in nature, explaining why optimal gain 
was above 1 (i.e., faster than target). Possibly, CIS patients had a 
lesser ability to perform predictive eye movements at this veloc-
ity. Nonetheless, the presence of abnormally elevated saccade 
amplitudes at slow speed, particularly catch-up saccades, does 
imply that overall pursuit gain is likely still sub-optimal in both 
CIS and CDMS patients. The use of sinusoidal tasks to evaluate 
overall gain may be better able to differentiate poor gain in these 
patients than testing optimal gain.
Curiously, a lower saccade count at fast target velocities was 
observed in both CIS and CDMS compared to controls, despite 
essentially identical saccade amplitudes overall. Patients therefore 
generated fewer saccades with greater amplitudes. The speed of 
25.9°/s is intentionally slightly under the upper limit of normal 
smooth pursuit (25), and the generation of high-amplitude 
saccades at this speed indicates a pathological lowering of the 
maximum pursuit gain. Our control data also imply that frequent 
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low-amplitude saccades are a normal compensatory mechanism 
at this velocity. Given the close interplay between saccades and 
pursuit during tracking (26), it is possible that injury to the 
complex system underlying the selection of different ocular 
movements has led to an impaired ability to correct position error 
in CIS and CDMS patients.
Delayed pursuit onset in CDMS patients in comparison to 
control participants signifies that in addition to feedback insuf-
ficiency, the initial generation of pursuit is compromised with 
disease progression. This is consistent with our previous findings 
for saccadic eye movements, where prolonged latencies become 
increasingly evident with longer disease durations (12).
Unexpectedly, we revealed no significant differences in 
performance between CDMS and CIS patients for any measure, 
although a number of visible trends suggest differential perfor-
mance with disease progression. This is possibly a consequence 
of the relatively low disease burden for our CDMS cohort (mean 
EDSS 1.3), or of low power. Comparing CIS patients with more 
advanced CDMS patients may allow for better discrimination 
between these two groups. Furthermore, correlations between 
pursuit abnormalities and EDSS scores, non-significant in the 
present study, may be more informative when conducted over a 
wider spectrum of disease severity. We intend to do this through 
our ongoing longitudinal studies.
Overall, our results provide further evidence that select ocular 
motor measures of performance can reflect clinically undetectable 
widespread neuronal injury at the earliest stages of MS (27). Given 
that more than 50% of cerebral circuitry is intimately involved in 
the control of vision and/or eye movements (28), disruption of 
these processes in the context of widespread structural damage is 
not only possible but expected.
Pursuit may therefore provide an inexpensive, fast, and 
objective tool for detecting widespread pathology in CIS 
and CDMS, with potential utility in identifying subclinical 
deficit. While both pursuit gain and saccade amplitudes may 
be robust markers of disease, it must be noted that gain 
was assessed solely during optimal pursuit, with segments 
of poorer pursuit ignored. This may explain why gain was 
seemingly normal for CDMS at slow and fast velocities, 
despite abnormal saccade profiles. Because summed saccade 
amplitude is independent from the subjective selection of 
an “optimal” pursuit segment, and also extremely quick and 
easy to calculate, it is likely the most appropriate variable for 
future clinical applications from those tested in this study. 
However, overall gain during each trial has the potential to 
be an effective discriminator, and we intend to examine this 
through sinusoidal tasks, which we are currently collecting 
data for. Furthermore, the medium pursuit velocity appears 
to best discriminate the presence of disease, particularly with 
respect to gain.
Measurement of pursuit latency, which is abnormally delayed 
in CDMS patients, may also be of clinical utility. Given the rela-
tively low disease burden of our CDMS cohort, it is possible that 
increased pursuit latency may provide a physiological marker 
contributing to staging of disease prior to substantial advances in 
the EDSS, potentially affording an early indicator for escalating 
therapy. Indeed, the observed trend for latency to increase as a 
function of disease stage (Figure 2) suggests that pursuit latency 
may be a marker of the extent of pathology. Further studies are 
crucially required to validate the utility of pursuit measures in 
discerning the presence and/or progression of disease in MS, 
and to examine if these are indeed beneficial in predicting 
disease progression before disability accumulation occurs. We 
are currently collecting the data for such longitudinal studies of 
individual patients.
It is important to note that we measured pursuit performance 
at the end of a testing battery including multiple ocular motor 
tasks. Fatigue may thus be a contributing factor to differential per-
formance between MS patients and controls. The test conductor 
and the data analyst were not blinded to each participant’s group, 
possibly increasing the likelihood of detection bias. However, 
gain and, in particular, saccade amplitudes, are highly objective 
markers and unlikely to have been significantly influenced by 
possible bias.
Our study is the first to investigate the relationship between 
disease stage and pursuit profile, and we have shown that smooth 
pursuit integrity is already substantially affected in CIS and early 
CDMS patients. Physiologically, this represents evidence of 
feedback loop dysfunction at the onset of clinical disease, with 
impairments in motor generation becoming evident at the early 
stages of CDMS. Smooth pursuit thus has promising utility as 
a cost-effective means of detecting early disseminated disease. 
Longitudinal studies are merited to examine whether pursuit 
deficits may be useful in predicting future conversion from CIS 
to CDMS, in monitoring disease activity, and in evaluating the 
need for therapy.
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